KR102354909B1 - 안정화된 중합체 실리케이트 조성물과 관련된 물질 및 방법 - Google Patents
안정화된 중합체 실리케이트 조성물과 관련된 물질 및 방법 Download PDFInfo
- Publication number
- KR102354909B1 KR102354909B1 KR1020167024827A KR20167024827A KR102354909B1 KR 102354909 B1 KR102354909 B1 KR 102354909B1 KR 1020167024827 A KR1020167024827 A KR 1020167024827A KR 20167024827 A KR20167024827 A KR 20167024827A KR 102354909 B1 KR102354909 B1 KR 102354909B1
- Authority
- KR
- South Korea
- Prior art keywords
- silicate
- composition
- delete delete
- stabilized
- less
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 title claims abstract description 201
- 239000000203 mixture Substances 0.000 title claims abstract description 200
- 238000000034 method Methods 0.000 title claims description 69
- 239000000463 material Substances 0.000 title description 24
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 57
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims abstract description 56
- 229920000642 polymer Polymers 0.000 claims abstract description 38
- 150000004760 silicates Chemical class 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 29
- 238000004090 dissolution Methods 0.000 claims abstract description 26
- 238000001990 intravenous administration Methods 0.000 claims abstract description 20
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 16
- 201000011510 cancer Diseases 0.000 claims abstract description 15
- 239000007787 solid Substances 0.000 claims abstract description 15
- 208000015181 infectious disease Diseases 0.000 claims abstract description 14
- 206010052428 Wound Diseases 0.000 claims abstract description 9
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 9
- 238000011200 topical administration Methods 0.000 claims abstract description 7
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 4
- 239000002245 particle Substances 0.000 claims description 93
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 45
- 229920001223 polyethylene glycol Polymers 0.000 claims description 41
- 239000002202 Polyethylene glycol Substances 0.000 claims description 40
- 239000003381 stabilizer Substances 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 33
- 229910052710 silicon Inorganic materials 0.000 claims description 29
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000010703 silicon Substances 0.000 claims description 28
- 239000006071 cream Substances 0.000 claims description 27
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- 239000002674 ointment Substances 0.000 claims description 24
- 229910052742 iron Inorganic materials 0.000 claims description 20
- 235000000346 sugar Nutrition 0.000 claims description 20
- 230000015572 biosynthetic process Effects 0.000 claims description 19
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 18
- 150000001768 cations Chemical class 0.000 claims description 16
- 229910052751 metal Inorganic materials 0.000 claims description 15
- 239000002184 metal Substances 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 14
- 238000003556 assay Methods 0.000 claims description 14
- 239000013589 supplement Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 241001465754 Metazoa Species 0.000 claims description 12
- 239000004115 Sodium Silicate Substances 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 12
- 229910052911 sodium silicate Inorganic materials 0.000 claims description 12
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 claims description 12
- VLAPMBHFAWRUQP-UHFFFAOYSA-L molybdic acid Chemical compound O[Mo](O)(=O)=O VLAPMBHFAWRUQP-UHFFFAOYSA-L 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000000499 gel Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 7
- 238000007911 parenteral administration Methods 0.000 claims description 7
- 208000001132 Osteoporosis Diseases 0.000 claims description 6
- 229910052910 alkali metal silicate Inorganic materials 0.000 claims description 6
- 230000000844 anti-bacterial effect Effects 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 208000012659 Joint disease Diseases 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 5
- -1 iron ions Chemical class 0.000 claims description 5
- 239000011159 matrix material Substances 0.000 claims description 5
- 238000006116 polymerization reaction Methods 0.000 claims description 5
- 230000029663 wound healing Effects 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 208000025865 Ulcer Diseases 0.000 claims description 4
- 239000002585 base Substances 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 238000007912 intraperitoneal administration Methods 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 231100000397 ulcer Toxicity 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 208000028698 Cognitive impairment Diseases 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 208000010877 cognitive disease Diseases 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 208000005368 osteomalacia Diseases 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 239000007995 HEPES buffer Substances 0.000 claims description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 claims description 2
- 239000004111 Potassium silicate Substances 0.000 claims description 2
- 239000000061 acid fraction Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 229910052914 metal silicate Inorganic materials 0.000 claims description 2
- 229910052913 potassium silicate Inorganic materials 0.000 claims description 2
- NNHHDJVEYQHLHG-UHFFFAOYSA-N potassium silicate Chemical compound [K+].[K+].[O-][Si]([O-])=O NNHHDJVEYQHLHG-UHFFFAOYSA-N 0.000 claims description 2
- 235000019353 potassium silicate Nutrition 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 208000019553 vascular disease Diseases 0.000 claims description 2
- 230000003648 hair appearance Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 4
- 230000009885 systemic effect Effects 0.000 abstract description 2
- 239000000725 suspension Substances 0.000 description 35
- 239000002105 nanoparticle Substances 0.000 description 30
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 14
- 229930006000 Sucrose Natural products 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 239000005720 sucrose Substances 0.000 description 14
- 230000000699 topical effect Effects 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 239000010949 copper Substances 0.000 description 10
- 238000011105 stabilization Methods 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 230000006641 stabilisation Effects 0.000 description 9
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000009833 condensation Methods 0.000 description 8
- 230000005494 condensation Effects 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 150000002772 monosaccharides Chemical class 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 7
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 7
- 238000007865 diluting Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 150000008163 sugars Chemical class 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 101150082840 SM30 gene Proteins 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 5
- 229910052802 copper Inorganic materials 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- QBEFIFWEOSUTKV-UHFFFAOYSA-N dimethylheptylpyran Chemical compound CC1(C)OC2=CC(C(C)C(C)CCCCC)=CC(O)=C2C2=C1CCC(C)C2 QBEFIFWEOSUTKV-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000004962 physiological condition Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001668 ameliorated effect Effects 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 229910021538 borax Inorganic materials 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 125000005624 silicic acid group Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000004328 sodium tetraborate Substances 0.000 description 3
- 235000010339 sodium tetraborate Nutrition 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 239000012085 test solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 208000031050 Skin vascular disease Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 208000024519 eye neoplasm Diseases 0.000 description 2
- 239000013020 final formulation Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000007954 growth retardant Substances 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 239000002114 nanocomposite Substances 0.000 description 2
- 201000008106 ocular cancer Diseases 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011181 potassium carbonates Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 230000009919 sequestration Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 235000019795 sodium metasilicate Nutrition 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 230000009278 visceral effect Effects 0.000 description 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- KEZYHIPQRGTUDU-UHFFFAOYSA-N 2-[dithiocarboxy(methyl)amino]acetic acid Chemical compound SC(=S)N(C)CC(O)=O KEZYHIPQRGTUDU-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- UNXHWFMMPAWVPI-QWWZWVQMSA-N D-threitol Chemical compound OC[C@@H](O)[C@H](O)CO UNXHWFMMPAWVPI-QWWZWVQMSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000805973 Multilamina Species 0.000 description 1
- 241001635529 Orius Species 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 238000003917 TEM image Methods 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229920006125 amorphous polymer Polymers 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000010945 base-catalyzed hydrolysis reactiony Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000001354 calcination Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000005493 condensed matter Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 125000005372 silanol group Chemical group 0.000 description 1
- MBRNTTZGBWIWQZ-UHFFFAOYSA-N silicic acid silver Chemical compound [Ag].O[Si](O)(O)O MBRNTTZGBWIWQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G77/00—Macromolecular compounds obtained by reactions forming a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon in the main chain of the macromolecule
- C08G77/02—Polysilicates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/34—Silicon-containing compounds
- C08K3/36—Silica
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L83/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen or carbon only; Compositions of derivatives of such polymers
- C08L83/02—Polysilicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K2201/00—Specific properties of additives
- C08K2201/011—Nanostructured additives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1402672.8 | 2014-02-14 | ||
| GB201402672A GB201402672D0 (en) | 2014-02-14 | 2014-02-14 | Materials and methods relating to stabilised polymeric silicate compositions |
| PCT/GB2015/050409 WO2015121666A1 (en) | 2014-02-14 | 2015-02-13 | Materials and methods relating to stabilised polymeric silicate compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160124797A KR20160124797A (ko) | 2016-10-28 |
| KR102354909B1 true KR102354909B1 (ko) | 2022-01-24 |
Family
ID=50440204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167024827A Active KR102354909B1 (ko) | 2014-02-14 | 2015-02-13 | 안정화된 중합체 실리케이트 조성물과 관련된 물질 및 방법 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20170042934A1 (enExample) |
| EP (1) | EP3105281B1 (enExample) |
| JP (1) | JP6618475B2 (enExample) |
| KR (1) | KR102354909B1 (enExample) |
| CN (1) | CN106164136B (enExample) |
| AU (1) | AU2015216711B2 (enExample) |
| CA (1) | CA2939419C (enExample) |
| EA (1) | EA034577B1 (enExample) |
| ES (1) | ES2872498T3 (enExample) |
| GB (1) | GB201402672D0 (enExample) |
| NZ (1) | NZ723746A (enExample) |
| SG (2) | SG10202000307VA (enExample) |
| WO (1) | WO2015121666A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3305305B1 (en) | 2007-10-15 | 2021-06-09 | HS Pharmaceuticals, LLC | Silicate containing compositions and methods of treatment |
| GB201507002D0 (en) * | 2015-04-24 | 2015-06-10 | Medical Res Council | Copper Oxo-hydroxide nanoparticles and their uses as biocidal agents |
| US20200268938A1 (en) * | 2016-04-01 | 2020-08-27 | Hs Pharmaceuticals, Llc | Novel bone putty compositions and methods of use thereof |
| US10604257B2 (en) * | 2016-06-28 | 2020-03-31 | International Business Machines Corporation | Unmanned aerial vehicle for air sampling |
| JP7510254B2 (ja) * | 2016-08-10 | 2024-07-03 | ユナイテッド キングダム リサーチ アンド イノベーション | ナノシリカ粒子を含む組成物および療法のためにｔリンパ球を活性化する方法におけるそれらの使用 |
| KR20180034937A (ko) | 2016-09-28 | 2018-04-05 | 모멘티브퍼포먼스머티리얼스코리아 주식회사 | 유기 전자 소자 봉지재용 조성물 및 이를 이용하여 형성된 봉지재 |
| GB201701944D0 (en) * | 2017-02-06 | 2017-03-22 | Medical Res Council | Antimicrobial compositions and their uses |
| KR102427987B1 (ko) | 2018-11-27 | 2022-08-02 | 주식회사 엘지화학 | 전가수분해된 폴리실리케이트의 합성방법 |
| WO2020218834A1 (ko) * | 2019-04-24 | 2020-10-29 | 윤종오 | 카르복실산으로 유기화된 규소 이온 복합체 및 복합체의 제조방법과 이를 이용한 제품 |
| KR102207608B1 (ko) * | 2019-04-24 | 2021-01-26 | 윤종오 | 카르복실산으로 유기화된 규소 이온 복합체 및 복합체의 제조방법과 이를 이용한 제품 |
| US20230021329A1 (en) * | 2019-12-20 | 2023-01-26 | Veri Nano Inc. | Nanostructured binary gel composition and use thereof |
| SE2450523A1 (en) * | 2024-02-22 | 2025-08-23 | Lea Cares Ab | Method to form supernatant |
| WO2025178550A1 (en) * | 2024-02-22 | 2025-08-28 | Lea Cares Ab | Method to form supernatant |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011529973A (ja) * | 2008-08-01 | 2011-12-15 | シーナトゥール ゲーエムベーハー | 生物学的活性ケイ酸 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1688228A (en) | 1928-10-16 | gebmany | ||
| US4029770A (en) | 1974-03-26 | 1977-06-14 | Caw Industries, Inc. | Method of therapeutically treating damaged and/or infected tissue and relieving stress and shock in warm blooded animals |
| US4563351A (en) | 1983-08-01 | 1986-01-07 | Forsyth Dental Infirmary For Children | Self-gelling therapeutic compositions for topical application |
| US5080900A (en) | 1990-04-17 | 1992-01-14 | Stanley R Thomas | Treatment of skin ulcers with an aqueous extract of oak bark ash |
| US7014870B1 (en) | 1992-11-06 | 2006-03-21 | Greystone Medical Group, Inc. | Compositions of oak bark extract related synthetic compositions and method of using same |
| AU700019B2 (en) | 1992-11-06 | 1998-12-17 | Greystone Medical Group, Inc. | Compositions of oak bark extract, related synthetic compositions, and method of using same |
| US5370876A (en) | 1993-01-08 | 1994-12-06 | Microbarriers | Antimicrobial protective skin composition and method for protecting skin from body fluids |
| JP2588109B2 (ja) | 1993-03-19 | 1997-03-05 | 日本臓器製薬株式会社 | 鎮痛剤 |
| NL9400189A (nl) | 1994-02-07 | 1995-09-01 | Bio Pharma Sciences Bv | Gestabiliseerd orthosiliciumzuur bevattend preparaat, een werkwijze voor het bereiden daarvan en een biologisch preparaat. |
| US20060246154A1 (en) | 1997-10-08 | 2006-11-02 | Hon David N | Composition of oak bark extract, related synthetic compositions, and method of using same |
| FR2799758B1 (fr) | 1999-10-15 | 2002-05-17 | Exsymol Sa | Complexe a base d'acide orthosilicique biologiquement assimilable, se presentant sous forme solide, stable et concentree, et procede de preparation |
| CA2298762C (en) | 2000-02-11 | 2001-06-12 | Paul M. Pidcock | Therapeutic compositions consisting of clarified multi-filtered soluable sodium silicate in liquid form are found to modify suppressor cells and enhanse the human immune system toprevent recurrence of herpes infections |
| KR100330993B1 (ko) | 2000-02-18 | 2002-04-01 | 김승일 | 액상 사료 첨가제 및 이의 제조방법 |
| RU2182006C2 (ru) | 2000-03-01 | 2002-05-10 | Цивинский Станислав Викторович | Способ лечения ревматоидного артрита |
| US6692775B2 (en) | 2000-03-13 | 2004-02-17 | Aqua Med, Inc. | Bactericidal gel and method for treating burns and dermal lesions |
| US6288045B1 (en) | 2000-06-09 | 2001-09-11 | Lifelink Pharmaceuticals, Inc. | Epithelial cell cancer drug |
| KR100331952B1 (ko) | 2000-11-23 | 2002-04-09 | 최수일 | 다목적 고기능성 알칼리 용액 조성물 및 그 제조방법과 비특이 면역증강제로서의 용도 |
| US20040057958A1 (en) | 2002-05-17 | 2004-03-25 | Waggoner David W. | Immunogenicity-enhancing carriers and compositions thereof and methods of using the same |
| UA80969C2 (en) | 2002-05-31 | 2007-11-26 | Aqueous solution of non-colloidal silicic and boric acids, method for its preparation and application | |
| AU2003262804A1 (en) | 2002-08-22 | 2004-03-11 | Nutrition 21, Inc. | Arginine silicate inositol complex and use thereof |
| RU2237483C1 (ru) | 2003-02-21 | 2004-10-10 | Цивинский Станислав Викторович | Средство для лечения гастрита с повышенной кислотностью и язвенной болезни и способ их лечения |
| EP1670719A1 (en) | 2003-05-15 | 2006-06-21 | RAJU, Kanumuru Rahul | Functional transition metal silicates (ftms) |
| CN100366534C (zh) * | 2004-05-09 | 2008-02-06 | 中国石化北京燕化石油化工股份有限公司 | 适用于阴离子聚合的层状硅酸盐的改性方法、由此得到的改性层状硅酸盐及其用途 |
| CN1315484C (zh) | 2004-11-16 | 2007-05-16 | 关相龙 | 治疗皮肤病的药物载体组合物及制备方法 |
| RU2280458C1 (ru) | 2004-11-30 | 2006-07-27 | Алевтина Ивановна Косолапова | Противовоспалительная мазь |
| DE102004063599B4 (de) | 2004-12-30 | 2007-07-12 | Bayer Innovation Gmbh | Verkürzte Wundheilungsprozesse mittels neuartiger Faservliese |
| NZ537747A (en) | 2005-01-18 | 2008-02-29 | Victoria Link Ltd | Nano-structured silicate, functionalised forms thereof, preparation and uses |
| CA2604751A1 (en) | 2005-04-20 | 2006-12-28 | Laboratoires Mauves Inc. | Organic silicic acids complex for therapeutic and cosmetic applications |
| US20070161539A1 (en) * | 2006-01-12 | 2007-07-12 | Enrique Hernandez | Method of regulating degree of polymerization of an alkali metal silicate in solution using pH |
| CA2673313A1 (en) | 2006-12-18 | 2008-12-04 | Amcol International | Virus-interacting layered phyllosilicates and methods of use |
| US20100278935A1 (en) | 2007-07-30 | 2010-11-04 | Stacey William C | Immune System Modulator Formulation |
| EP3305305B1 (en) | 2007-10-15 | 2021-06-09 | HS Pharmaceuticals, LLC | Silicate containing compositions and methods of treatment |
| US20110009486A1 (en) | 2008-03-03 | 2011-01-13 | Luna Innovations Incorporated | Method for treating pruritus by administering fullerenes |
| WO2009127256A1 (en) * | 2008-04-17 | 2009-10-22 | Jisbrey, S.A | Hydronium stabilized and dissoluble silicic acid nanoparticles: preparation, stabilization and use |
| PL2371220T3 (pl) * | 2010-03-31 | 2015-04-30 | Taminco | Stabilizowany, biologicznie dostępny roztwór rozpuszczalnego krzemianu |
| EP2632432B1 (en) * | 2010-10-26 | 2020-09-30 | Paragon Nordic AB | Composition and method for treating wounds |
| GB201402669D0 (en) * | 2014-02-14 | 2014-04-02 | Medical Res Council | Stabilised silicate compositions and their uses |
-
2014
- 2014-02-14 GB GB201402672A patent/GB201402672D0/en not_active Ceased
-
2015
- 2015-02-13 EP EP15707169.7A patent/EP3105281B1/en active Active
- 2015-02-13 EA EA201691441A patent/EA034577B1/ru unknown
- 2015-02-13 AU AU2015216711A patent/AU2015216711B2/en active Active
- 2015-02-13 CN CN201580018382.3A patent/CN106164136B/zh active Active
- 2015-02-13 CA CA2939419A patent/CA2939419C/en active Active
- 2015-02-13 KR KR1020167024827A patent/KR102354909B1/ko active Active
- 2015-02-13 JP JP2016551833A patent/JP6618475B2/ja active Active
- 2015-02-13 ES ES15707169T patent/ES2872498T3/es active Active
- 2015-02-13 WO PCT/GB2015/050409 patent/WO2015121666A1/en not_active Ceased
- 2015-02-13 NZ NZ723746A patent/NZ723746A/en unknown
- 2015-02-13 US US15/119,071 patent/US20170042934A1/en not_active Abandoned
- 2015-02-13 SG SG10202000307VA patent/SG10202000307VA/en unknown
- 2015-02-13 SG SG10202007920RA patent/SG10202007920RA/en unknown
-
2018
- 2018-10-24 US US16/169,437 patent/US10898511B2/en active Active
-
2020
- 2020-12-15 US US17/121,884 patent/US11833171B2/en active Active
-
2023
- 2023-10-27 US US18/495,938 patent/US20240066053A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011529973A (ja) * | 2008-08-01 | 2011-12-15 | シーナトゥール ゲーエムベーハー | 生物学的活性ケイ酸 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20190224233A1 (en) | 2019-07-25 |
| CA2939419C (en) | 2022-07-26 |
| US20210145866A1 (en) | 2021-05-20 |
| EA034577B1 (ru) | 2020-02-21 |
| AU2015216711B2 (en) | 2018-08-09 |
| US10898511B2 (en) | 2021-01-26 |
| AU2015216711A1 (en) | 2016-09-22 |
| KR20160124797A (ko) | 2016-10-28 |
| EP3105281B1 (en) | 2021-04-21 |
| SG10202000307VA (en) | 2020-03-30 |
| CN106164136A (zh) | 2016-11-23 |
| US20240066053A1 (en) | 2024-02-29 |
| NZ723746A (en) | 2022-09-30 |
| GB201402672D0 (en) | 2014-04-02 |
| ES2872498T3 (es) | 2021-11-02 |
| CA2939419A1 (en) | 2015-08-20 |
| HK1226424A1 (zh) | 2017-09-29 |
| CN106164136B (zh) | 2019-11-08 |
| JP6618475B2 (ja) | 2019-12-11 |
| SG10202007920RA (en) | 2020-10-29 |
| EA201691441A1 (ru) | 2017-02-28 |
| US20170042934A1 (en) | 2017-02-16 |
| JP2017512189A (ja) | 2017-05-18 |
| WO2015121666A1 (en) | 2015-08-20 |
| US11833171B2 (en) | 2023-12-05 |
| EP3105281A1 (en) | 2016-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102354909B1 (ko) | 안정화된 중합체 실리케이트 조성물과 관련된 물질 및 방법 | |
| JP6775523B2 (ja) | オキソ水酸化銅ナノ粒子を含む抗細菌組成物およびそれらの殺生物剤としての使用 | |
| EP2861212B1 (en) | Nanoceria for the treatment of oxidative stress | |
| JP7634505B2 (ja) | ナノシリカ粒子を含む組成物および療法のためにｔリンパ球を活性化する方法におけるそれらの使用 | |
| KR20160124762A (ko) | 안정화된 규산염 조성물 및 발한억제 조성물로서 이의 용도 | |
| HK1226424B (en) | Materials and methods relating to stabilised polymeric silicate compositions | |
| Garcia Villen | Aplicaciones farmacéuticas de aluminosilicatos mesoporosos: estudio de arcillas fibrosas (sepiolita y palygorskita) en geles con agua mineromedicinal | |
| EP3607956A1 (en) | Bioproduct based on selenium nanoparticles in a honey matrix for the treatment of complex injuries and dermatological infections | |
| JP2023520709A (ja) | 肝疾患と関連する鉄欠乏症の治療または予防における使用のためのカルボン酸塩リガンド修飾水酸化第二鉄組成物 | |
| HK40007601B (en) | Compositions comprising nanosilica particles and their use in methods of activating t lymphocytes for therapy | |
| MX2010005475A (es) | La lidocaina como transformadora y productora de complejos de farmacos trasformados aplicados en nanodosis mediante implantes por inyeccion como dispositivos de liberacion prolongada. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20160907 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PN2301 | Change of applicant |
Patent event date: 20190211 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200212 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20210421 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20211228 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20220119 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20220120 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20250110 Start annual number: 4 End annual number: 4 |